Navigation Links
Liver-cell transplants show promise in reversing genetic disease affecting liver and lungs
Date:4/22/2011

April 21, 2011 -- (Bronx, NY) -- Transplanting cells from healthy adult livers may work in treating a genetic liver-lung disorder that affects millions of people worldwide, according to an animal study in the April 18 online edition of the Journal of Clinical Investigation. Jayanta Roy-Chowdhury, M.D. , professor of medicine and of genetics at Albert Einstein College of Medicine of Yeshiva University, is the study's senior author.

The genetic disorder, alpha-1 antitrypsin (AAT) deficiency, is the most common potentially lethal hereditary disease among Caucasians, affecting an estimated 100,000 people in the United States and 3.4 million people worldwide. AAT is a protein made by the liver that is essential for lung health. In AAT deficiency, the liver produces a misshapen form of AAT that cannot enter the bloodstream and instead gets stuck inside liver cells, causing two major problems:

  • AAT accumulates in the liver, leading to fibrosis (development of scar tissue) and liver failure;
  • Too little AAT reaches the lungs, where it's needed to rein in elastase, an enzyme produced by white blood cells. Elastase helps kill bacteria in the lungs, but uncontrolled elastase activity can damage lung tissue and lead to severe emphysema (chronic obstructive pulmonary disease).
  • In the study, Dr. Roy-Chowdhury and his colleagues tested cell therapy on transgenic mice whose liver cells (hepatocytes) had been engineered to produce mutant human AAT, resulting in liver fibrosis. When the mice were given infusions of hepatocytes harvested from the livers of healthy mice, the transplanted cells proliferated in the host liver, progressively replacing diseased hepatocytes. Most importantly, said Dr. Roy-Chowdhury, the transplanted cells reversed the fibrosis that had developed.

    Current therapy for AAT deficiency consists of life-long injections of a genetically engineered version of AAT called Prolastin. "This very expensive therapy slows progression of the lung disease in some patients but does not have any beneficial effect on the liver disease," said Dr. Roy-Chowdhury. The only other therapy for AAT deficiency is combined lung-liver transplantation, which is reserved for the sickest patients.

    "These promising results in animals indicate that it may be worthwhile to investigate the usefulness of hepatocyte transplantation for AAT deficiency as well as a variety of other inherited liver-based disorders," said Dr. Roy-Chowdhury.


    '/>"/>

    Contact: Kim Newman
    sciencenews@einstein.yu.edu
    718-430-3101
    Albert Einstein College of Medicine
    Source:Eurekalert

    Related medicine news :

    1. Internal Anthem Blue Cross/WellPoint Document: Only Patients Who Push Back Get Covered Out of State Liver Transplants
    2. Los Angeles Hair Transplant Cosmetic Surgeon Corrects Bad Hair Transplants With New Hair Restoration Method
    3. Kidney transplants: Expanding the pool of available organs
    4. Patients with treatment-resistant CLL respond positively to stem cell transplants
    5. Hispanics and Asians less likely to receive liver transplants
    6. Biosynthetic Corneas Show Promise in Transplants
    7. OHSU research suggests compound administered during some bone marrow transplants elevates risks
    8. Kidney Transplants for Elderly Double Over Decade
    9. HIV Patients Do Well After Kidney Transplants: Study
    10. 2 people receive kidney transplants in pilot program using CMU software
    11. Gene protects lung from damage due to pneumonia, sepsis, trauma, transplants
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/26/2016)... Miami, FL (PRWEB) , ... May 26, 2016 , ... ... day of events featuring guest speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis ... Anti-Aging and Regenerative Medicine, and a member of the Institute for Functional Medicine. , ...
    (Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the ... bunionette) treatment was more than humbled by customer demand over the Mother’s Day Weekend ... mid sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes ...
    (Date:5/26/2016)... Redwood City, CA (PRWEB) , ... May 26, 2016 , ... ... time, Silicon Valley-based startup, The Dough Bar, has ignited an undeniable buzz ... shake -- a doughnut. But not just any doughnut.  These doughnuts are packed with ...
    (Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & Associates’ ... 20 years of experience in leading technology and human resources operations for health ... teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , Innovative ...
    (Date:5/26/2016)... ... , ... Dr. LeRoy Perry’s recently authored whitepaper, “Tech Neck and ROI (return ... of users, hundreds of millions of whom are coming into the workplace with pain ... common action of looking down at hand-held technology devices (tablets, smartphones) for extended periods ...
    Breaking Medicine News(10 mins):
    (Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
    (Date:5/25/2016)... Germany and GERMANTOWN, Maryland , ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... agreement with Therawis Diagnostics GmbH to develop and commercialize predictive ... and market PITX2 as a marker to predict effectiveness of ... patients. "We are pleased to partner with Therawis, ...
    (Date:5/25/2016)... 25, 2016 According to market ... Growth and Demand Forecast to 2022 - Industry Insights ... Others)" published by P&S Market Research, the global insulin ... 2015, and it is expected to grow at a ... insulin pump segment is expected to witness the fastest ...
    Breaking Medicine Technology: